Results 211 to 220 of about 187,323 (286)

Conservation status of species used in the UK herbal medicine industry

PLANTS, PEOPLE, PLANET, EarlyView.
Given the ongoing biodiversity crisis, sustainable use and management of medicinal plants is critical. We assessed the conservation status, threats and conservation actions of 298 species sold by UK suppliers to medical herbalists. We found that most species used are unevaluated, representing a gap in conservation knowledge, and of those with ...
Isabella Flowers, Jon C. Lovett, Christopher Hassall   +2 more
wiley   +1 more source

Amino acid starvation and iron limitation facilitate the biofilm formation of <i>Klebsiella pneumoniae</i> within urine. [PDF]

Biofilm
Pan X, Zhu Y, Zhang Y, Zhao J, Gao X, Li C, Yu Y, Ma J.   +7 more
europepmc   +1 more source

Automated quality assurance of HDR brachytherapy: Evaluation of Dwell‐position accuracy and Dwell‐time linearity via image processing of radiochromic films

Precision Radiation Oncology, EarlyView.
This study develops a method combining radiochromic film and image processing to assess HDR brachytherapy source accuracy and linearity, achieving high precision and efficiency . Abstract Purpose To develop and validate a fully automated quality assurance method for high‐dose rate (HDR) brachytherapy, enabling the precise evaluation of source dwell ...
Qingqing Yuan, Suyan Bi, En Lou, YaJun Jia, Zhitao Dai   +4 more
wiley   +1 more source

Mechanistic insights into Rottlerin's inhibition of MrkH-mediated biofilm and capsule formation in Klebsiella pneumoniae. [PDF]

BMC Microbiol
Hanna RS, Sebak M, Sayed AM, El-Gendy AO, Taha MN.   +4 more
europepmc   +1 more source

Ashwagandha: Is It Safe? Part 2: A Preclinical Evidence Review

Phytotherapy Research, EarlyView.
ABSTRACT The preclinical evidence for the safety of ashwagandha (Withania somnifera (L.) Dunal, AS) is reviewed, and its preparations (extracts) and constituents, from the general toxicity in animal models to in vitro and cell culture studies, which may elucidate mechanisms of action and explain clinical case reports.
Elizabeth M. Williamson, Thomas Brendler
wiley   +1 more source

A Biologically Inert Tamoxifen-derived Long-lasting Hydrogel-mediated Immunochemotherapy Can Mitigate Tumour Progression and Activate T Cell Immunity. [PDF]

Chem Mater
Jha SK, Kumar S, Jain D, Pandey N, Chakraborty R, Rana K, Mehta D, Nath D, Ralhan J, Saini M, Chourasiya NK, Rani P, Pal S, Sengupta S, Pal A, Bajaj A.   +15 more
europepmc   +1 more source

Ashwagandha: Is It Safe? Part 1: A Regulatory Review

Phytotherapy Research, EarlyView.
ABSTRACT Over the last decade, ashwagandha (Withania somnifera (L.) Dunal, AS) has been brought under increasing scrutiny by EU regulators regarding its safety for the use in food supplements, culminating in a recent recommendation for an Article 8 procedure according to Regulation (EC) No. 1925/2006 in the European Union (EU).
T. Brendler, R. Al‐Mondhiry, L. Lang, R. Marles, M. Tallon, A. Raghu   +5 more
wiley   +1 more source

Contribution of two-component regulatory systems to the acute-to-chronic infection transition of <i>Pseudomonas aeruginosa</i> in cystic fibrosis. [PDF]

J Bacteriol
Flores-Vega VR, Hernández-Martínez G, Cocotl-Yañez M, Ares MA, Lincopan N, Ortiz-Navarrete V, Rosales-Reyes R.   +6 more
europepmc   +1 more source

Hederagenin Attenuates Cardiac Remodeling by Targeting Phosphodiesterase 9A

Phytotherapy Research, EarlyView.
ABSTRACT Background and Aim New therapeutic strategies for heart failure are urgently needed. The protective effects of cyclic guanosine monophosphate (cGMP)—protein kinase G (PKG) pathway on heart have been widely reported. Despite phosphodiesterase 9A (PDE9A) inhibitors combating cardiac remodeling, clinically available drugs are lacking. Hederagenin
Liqian Chen, Xinghong Zhou, Yanting You, Jieyu Chen, Baizhao Peng, Yijian Deng, Shuai Ji, Ying Yang, Xiaohu Chen, Huaxi Liu, Shuxuan Yang, Hiu Yee Kwan, Wen Jin, Lei Zhang, Yuegang Wang, Xiaoshan Zhao, Yanyan Liu   +16 more
wiley   +1 more source

Clinical feasibility and cost efficiency of perinatal mesenchymal stem cell production under GMP conditions. [PDF]

Sci Rep
Çopuroğlu M, Yalçın ÖT, Kara SG.
europepmc   +1 more source